Xavier Pares

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4823807/publications.pdf

Version: 2024-02-01

39 papers	1,565 citations	361045 20 h-index	301761 39 g-index
39 all docs	39 docs citations	39 times ranked	1570 citing authors

#	Article	IF	Citations
1	Expansion of the 4-(Diethylamino)benzaldehyde Scaffold to Explore the Impact on Aldehyde Dehydrogenase Activity and Antiproliferative Activity in Prostate Cancer. Journal of Medicinal Chemistry, 2022, 65, 3833-3848.	2.9	7
2	Structural and biochemical evidence that ATP inhibits the cancer biomarker human aldehyde dehydrogenase 1A3. Communications Biology, 2022, 5, 354.	2.0	6
3	Design, Synthesis, Biological Evaluation and In Silico Study of Benzyloxybenzaldehyde Derivatives as Selective ALDH1A3 Inhibitors. Molecules, 2021, 26, 5770.	1.7	8
4	Perspective on the Structural Basis for Human Aldo-Keto Reductase 1B10 Inhibition. Metabolites, 2021, 11, 865.	1.3	1
5	Synthesis of C11-to-C14 methyl-shifted all-trans-retinal analogues and their activities on human aldo-keto reductases. Organic and Biomolecular Chemistry, 2020, 18, 4788-4801.	1.5	1
6	Structural and kinetic features of aldehyde dehydrogenase 1A (ALDH1A) subfamily members, cancer stem cell markers active in retinoic acid biosynthesis. Archives of Biochemistry and Biophysics, 2020, 681, 108256.	1.4	22
7	Engineering aldo-keto reductase 1B10 to mimic the distinct 1B15 topology and specificity towards inhibitors and substrates, including retinoids and steroids. Chemico-Biological Interactions, 2019, 307, 186-194.	1.7	7
8	Efficacy of aldose reductase inhibitors is affected by oxidative stress induced under X-ray irradiation. Scientific Reports, 2019, 9, 3177.	1.6	11
9	Inhibitors of aldehyde dehydrogenases of the 1A subfamily as putative anticancer agents: Kinetic characterization and effect on human cancer cells. Chemico-Biological Interactions, 2019, 306, 123-130.	1.7	17
10	Design, synthesis, structure-activity relationships and X-ray structural studies of novel 1-oxopyrimido[4,5-c]quinoline-2-acetic acid derivatives as selective and potent inhibitors of human aldose reductase. European Journal of Medicinal Chemistry, 2018, 152, 160-174.	2.6	26
11	Structural basis for the inhibition of AKR1B10 by the C3 brominated TTNPB derivative UVI2008. Chemico-Biological Interactions, 2017, 276, 174-181.	1.7	3
12	Characterization of AKR1B16, a novel mouse aldo-keto reductase. Chemico-Biological Interactions, 2017, 276, 182-193.	1.7	4
13	IDD388 Polyhalogenated Derivatives as Probes for an Improved Structure-Based Selectivity of AKR1B10 Inhibitors. ACS Chemical Biology, 2016, 11, 2693-2705.	1.6	19
14	Enantioselective Synthesis of Vicinal (R , R)-Diols by Saccharomyces cerevisiae Butanediol Dehydrogenase. Applied and Environmental Microbiology, 2016, 82, 1706-1721.	1.4	14
15	The yeast Î¶â€crystallin/NADPH:quinone oxidoreductase (Zta1p) is under nutritional control by the target of rapamycin pathway and is involved in the regulation of argininosuccinate lyase <scp>mRNA</scp> halfâ€life. FEBS Journal, 2015, 282, 1953-1964.	2.2	6
16	Structural Determinants of the Selectivity of 3â€Benzyluracilâ€1â€acetic Acids toward Human Enzymes Aldose Reductase and AKR1B10. ChemMedChem, 2015, 10, 1989-2003.	1.6	13
17	Substrate Specificity, Inhibitor Selectivity and Structure-Function Relationships of Aldo-Keto Reductase 1B15: A Novel Human Retinaldehyde Reductase. PLoS ONE, 2015, 10, e0134506.	1.1	17
18	Structural analysis of sulindac as an inhibitor of aldose reductase and AKR1B10. Chemico-Biological Interactions, 2015, 234, 290-296.	1.7	22

#	Article	IF	Citations
19	Human prostaglandin reductase 1 (PGR1): Substrate specificity, inhibitor analysis and site-directed mutagenesis. Chemico-Biological Interactions, 2015, 234, 105-113.	1.7	24
20	A missense mutation in ALDH1A3 causes isolated microphthalmia/anophthalmia in nine individuals from an inbred Muslim kindred. European Journal of Human Genetics, 2014, 22, 419-422.	1.4	19
21	Identification of a novel polyfluorinated compound as a lead to inhibit the human enzymes aldose reductase and AKR1B10: structure determination of both ternary complexes and implications for drug design. Acta Crystallographica Section D: Biological Crystallography, 2014, 70, 889-903.	2.5	28
22	X-ray structure of the V301L aldoâ€“keto reductase 1B10 complexed with NADP+ and the potent aldose reductase inhibitor fidarestat: Implications for inhibitor binding and selectivity. Chemico-Biological Interactions, 2013, 202, 178-185.	1.7	14
23	Biological Role of Aldoâ€“Keto Reductases in Retinoic Acid Biosynthesis and Signaling. Frontiers in Pharmacology, 2012, 3, 58.	1.6	66
24	Human and rodent aldoâ€“keto reductases from the AKR1B subfamily and their specificity with retinaldehyde. Chemico-Biological Interactions, 2011, 191, 199-205.	1.7	29
25	Three-dimensional Structure and Enzymatic Function of Proapoptotic Human p53-inducible Quinone Oxidoreductase PIG3. Journal of Biological Chemistry, 2009, 284, 17194-17205.	1.6	48
26	Aldo-keto reductases from the AKR1B subfamily: Retinoid specificity and control of cellular retinoic acid levels. Chemico-Biological Interactions, 2009, 178, 171-177.	1.7	70
27	Structural basis for the high all-trans -retinaldehyde reductase activity of the tumor marker AKR1B10. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20764-20769.	3.3	172
28	Comparative functional analysis of human medium-chain dehydrogenases, short-chain dehydrogenases/reductases and aldo-keto reductases with retinoids. Biochemical Journal, 2006, 399, 101-109.	1.7	114
29	Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism. Biochemical Journal, 2003, 373, 973-979.	1.7	152
30	Distribution of alcohol dehydrogenase mRNA in the rat central nervous system.. FEBS Journal, 2001, 268, 5045-5056.	0.2	14
31	Genetic polymorphism of alcohol dehydrogenase in europeans: TheADH2*2 allele decreases the risk for alcoholism and is associated withADH3*1. Hepatology, 2000, 31, 984-989.	3.6	230
32	Retinoids, Ï‰-hydroxyfatty acids and cytotoxic aldehydes as physiological substrates, and H2-receptor antagonists as pharmacological inhibitors, of human class IV alcohol dehydrogenase. FEBS Letters, 1998, 426, 362-366.	1.3	69
33	Alcohol dehydrogenase of human and rat blood vessels. FEBS Letters, 1997, 405, 26-30.	1.3	50
34	Molecular modelling of human gastric alcohol dehydrogenase (class IV) and substrate docking: differences towards the classical liver enzyme (class I). FEBS Letters, 1996, 395, 99-102.	1.3	21
35	Arabidopsis Formaldehyde Dehydrogenase. Molecular Properties of Plant Class III Alcohol Dehydrogenase Provide Further Insights into the Origins, Structure and Function of Plant Class P and Liver Class I Alcohol Dehydrogenases. FEBS Journal, 1996, 241, 849-857.	0.2	81
36	Class III alcohol dehydrogenase fromSaccharomyces cerevisiae: Structural and enzymatic features differ toward the human/mammalian forms in a manner consistent with functional needs in formaldehyde detoxication. FEBS Letters, 1995, 370, 23-26.	1.3	39

#	Article	IF	Citations
37	Alcohol Dehydrogenase of Class IV (sigmasigma-ADH) from Human Stomach. cDNA Sequence and Structure/Function Relationships. FEBS Journal, 1994, 224, 549-557.	0.2	65
38	Cephalopod alcohol dehydrogenase: purification and enzymatic characterization. FEBS Letters, 1993, 328, 235-238.	1.3	23
39	Determinants of Ethanol and Acetaldehyde Metabolism in Chronic Alcoholics. Alcoholism: Clinical and Experimental Research, 1993, 17, 48-53.	1.4	33